Regulators in the European Union are recommendeding that tolebrutinib be approved as a treatment for people with secondary progressive multiple sclerosis (SPMS) who have not experienced a relapse in the last two years. That new positive opinion was issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), a regulatory body […]
The post EU experts back tolebrutinib approval for SPMS patients with no relapses appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com